9-羟基-5,8a-二甲基-1-亚甲基-3a,4,5,5a,9,9a-六氢薁并[7,6-D]呋喃-2,8-二酮 | 73680-94-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 9-羟基-5,8a-二甲基-1-亚甲基-3a,4,5,5a,9,9a-六氢薁并[7,6-D]呋喃-2,8-二酮
• 英文名称: Helenalin
• 英文别名: Sample A of helenalin；9-hydroxy-5,8a-dimethyl-1-methylidene-3a,4,5,5a,9,9a-hexahydroazuleno[6,7-b]furan-2,8-dione
• CAS: 73680-94-1
• 化学式: C₁₅H₁₈O₄
• 分子量: 262.306
• InChiKey: ZVLOPMNVFLSSAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] TRIARYLPYRIDINE COMPOUNDS AND USE THEREOF FOR TREATING CANCER<br/>[FR] COMPOSÉS DE TRIARYLPYRIDINE ET LEUR UTILISATION DANS LE CADRE DU TRAITEMENT DU CANCER
  申请人：INST NAT SANTE RECH MED

  公开号：WO2021239976A1

  公开（公告）日：2021-12-02

  The invention relates to new bis-triazole 2,4,6-triarylpyridines compounds and their use in the field of oncology, in particular in the prevention and/or treatment of cancer disease. The inventors have observed that the new bis-triazole 2,4,6-triarylpyridines were able to induce cancer cells death either as a standalone or, synergistically, in combination with a lysosomotropic agent, such as chloroquine. The compounds were active against a variety of cancer cells such as HeLa (cervical cancer cell), A549 (lung carcinoma), and PDX-2 or PDX-3 (lung adenocarcinoma). The invention also relates to compositions and methods for prevention and/or treatment of cancer diseases using the new bis-triazole 2,4,6-triarylpyridines compounds.

  该发明涉及新的双三唑基2,4,6-三芳基吡啶化合物及其在肿瘤学领域的应用，特别是在预防和/或治疗癌症疾病方面。发明人发现，新的双三唑基2,4,6-三芳基吡啶能够单独或与溶酶体靶向药物（如氯喹）联合，协同诱导癌细胞死亡。这些化合物对多种癌细胞具有活性，如HeLa（宫颈癌细胞）、A549（肺癌）和PDX-2或PDX-3（肺腺癌）。该发明还涉及使用新的双三唑基2,4,6-三芳基吡啶化合物预防和/或治疗癌症疾病的组合物和方法。
• USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS
  申请人：University of Kentucky

  公开号：US20150259356A1

  公开（公告）日：2015-09-17

  The present invention provides compounds of the formula (I) wherein: X 1 , X 2 and X 3 are heteroatoms; R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 are independently selected from H, halo, —OH, —NO 2 , —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C 1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR 1 —, —C(O)NR 1 NR 2 —, —C(O)O—, —OC(O)—, —NR 1 CO 2 —, —O—, —NR 1 C(O)NR 2 —, —OC(O)NR 1 —, —NR 1 NR 2 —, —NR 1 C(O)—, —S—, —SO—, —SO 2 —, —NR 1 —, —SO 2 NR 1 —, —NR 1 R 2 , or —NR 1 SO 2 —, wherein R 1 and R 2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR 1 R 2 , R 1 and R 2 optionally together with the nitrogen atom form an optionally substituted 5-12 membered ring, said ring optionally comprising 1 or more heteroatoms or a group selected from —CO—, —SO—, —SO 2 — and —PO—; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  本发明提供了以下式（I）的化合物： 其中： X1，X2和X3是杂原子； R4，R5，R6，R7，R8，R9和R10分别选自H，卤素，—OH，—NO2，—CN和可选地取代的脂肪族，环烷基，杂环烷基，芳基或杂芳基；以及 Z是可选地取代的C1-8直链或支链脂肪族，可选地含有1个或多个双键或三键，其中一个或多个碳原子可选地被R*取代，其中R*是可选地取代的环烷基，杂环烷基，芳基或杂芳基；氨基酸残基，H，—CN，—C（O）—，—C（O）C（O）—，—C（O）NR1—，—C（O）NR1NR2—，—C（O）O—，—OC（O）—，—NR1CO2—，—O—，—NR1C（O）NR2—，—OC（O）NR1—，—NR1NR2—，—NR1C（O）—，—S—，—SO—，—SO2—，—NR1—，—SO2NR1—，—NR1R2，或—NR1SO2—，其中R1和R2分别选自H和可选地取代的脂肪族，环烷基，杂环烷基，芳基或杂芳基；或者当R*为NR1R2时，R1和R2可选地与氮原子一起形成一个可选地取代的5-12成员环，所述环可选地包含1个或多个杂原子或从—CO—，—SO—，—SO2—和—PO—中选择的基团；或者其药学上可接受的盐，酯或前药。
• 3-METHYLIDENEOXAN-4-ONE COMPOUNDS AND SUBSTITUTED DERIVATIVES THEREOF AS INHIBITORS OF TELOMERASE
  申请人：NORTHWESTERN UNIVERSITY

  公开号：US20210070725A1

  公开（公告）日：2021-03-11

  Disclosed are 3-methylideneoxan-4-one compounds, derivatives thereof, and methods of their synthesis and methods of their use in treating a disease or disorder in a subject in need thereof, such as diseases and disorders that are associated with telomerase activity such as cancer. The disclosed compounds may be formulated in a pharmaceutical composition for treating diseases and disorders that are associated with telomerase activity such as cancer.

  本文披露了3-甲基亚氧杂环丙烯-4-酮化合物及其衍生物，以及它们的合成方法和在治疗患有疾病或障碍的受试者中的使用方法，例如与端粒酶活性相关的疾病和障碍，如癌症。披露的化合物可以制成药物组合物，用于治疗与端粒酶活性相关的疾病和障碍，如癌症。
• [EN] METHODS AND COMPOSITIONS FOR TERPENOID SYNTHESIS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LA SYNTHÈSE DE TERPÉNOÏDES
  申请人：UNIV FLORIDA

  公开号：WO2018053322A1

  公开（公告）日：2018-03-22

  In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are γ-allyl Knoevenagel adducts or quasi γ-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise α-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

  在一个方面，本公开涉及制备萜烯和类萜烯分子的方法。在另一个方面，本公开涉及所述方法的产物，即使用所述方法制备的萜烯和类萜烯分子。公开了合成各种萜烯类化合物的中间体γ-烯丙基Knoevenagel加合物或准γ-烯丙基Knoevenagel加合物。在各个方面，公开了通过这些中间体制备萜烯类化合物的方法。这些方法可以包括烯丙基亲电试剂的α-烷基化，然后通过环闭合重排生成多环萜烯结构。在另一个方面，本公开涉及萜烯类骨架，以及通过公开的氧化和取代反应在所述萜烯类骨架上制备的化合物。本摘要旨在作为在特定领域进行搜索的扫描工具，并不旨在限制本公开。
• Dioxolane analogs for improved inter-cellular delivery
  申请人：Shire BioChem Inc.

  公开号：US20030013660A1

  公开（公告）日：2003-01-16

  Dioxolane analogs of the following formula: 1 wherein R1 and R2 are defined herein, are useful in the treatment of cancer. For example, the compounds can be used to treat patients with cancer in which the cancer cells are deficient in nucleoside or nucleoside base transporters.

  以下式中的二氧杂环戊烷类似物：其中R1和R2在此处定义，可用于治疗癌症。例如，这些化合物可用于治疗癌症患者，这些患者的癌细胞缺乏核苷或核苷碱基转运蛋白。